A05生物製劑(生物藥、抗體、蛋白質、疫苗)、B04體外診斷用醫材(IVD)與服務

SYNG Pharmaceuticals Inc. (SYNG Pharma) is an emerging stage biotech developing a new first-in-class diagnostic test and therapeutic for endometriosis. SYNG Pharma's non-invasive ELISA Test EndoID is available for commercialization as a lab-based screening test.

Endometriosis impacts over 200 million women worldwide, is an over $2B market with no simple diagnostic or non-hormonal therapy. Therapy – SYNG has completed animal and toxicity studies for a peptide-based non-hormonal therapy for endometriosis to replace currently available drugs with significant side effects. Diagnostic - SYNG Pharma is ready to commercialize a simple blood-test EndoID. SYNG has completed POC prototypes for at-home use lateral flow device for women to screen endometriosis.